Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo, Jason Beattie, Paige Fuentes, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 10, pp. 1759-1764
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1381-1394
Closed Access | Times Cited: 112
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 74
Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges
Lily Dara, Eleonora De Martin
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 2
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
Lukas M. Braun, Sophie Giesler, Geoffroy Andrieux, et al.
Cancer Cell (2025) Vol. 43, Iss. 2, pp. 269-291.e19
Open Access | Times Cited: 2
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Laura Kalfeist, Loïck Galland, Fanny Ledys, et al.
Cells (2022) Vol. 11, Iss. 5, pp. 770-770
Open Access | Times Cited: 51
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Haonan Li, Qiang Luo, Hu Zhang, et al.
Chemical Society Reviews (2022) Vol. 52, Iss. 1, pp. 47-96
Closed Access | Times Cited: 44
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3798-3798
Open Access | Times Cited: 43
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
Morven Cunningham, Rohit Gupta, Marcus O. Butler
Hepatology (2023) Vol. 79, Iss. 1, pp. 198-212
Closed Access | Times Cited: 25
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Dirk Tomsitz, Theresa Ruf, Sarah Zierold, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2538-2538
Open Access | Times Cited: 22
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Corticosteroid-resistant immune-related adverse events: a systematic review
Eveline Daetwyler, Till Wallrabenstein, David König, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007409-e007409
Open Access | Times Cited: 11
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
Theresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114028-114028
Open Access | Times Cited: 10
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
T. Anders Olsen, Tony Zhuang, Sarah Caulfield, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 30
Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases
Antonio Pizuorno Machado, Malek Shatila, Cynthia Liu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6341-6350
Open Access | Times Cited: 19
Management of immune-related cutaneous adverse events with dupilumab
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph R. Stoll, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e007324-e007324
Open Access | Times Cited: 19
Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
Janaki Manoja Vinnakota, Rachael C. Adams, Dimitrios Athanassopoulos, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 751
Closed Access | Times Cited: 7
A Comprehensive Global Population-Based Analysis on the Coexistence of Eosinophilic Esophagitis and Inflammatory Bowel Disease
Alexander Malik, Benjamin D. Liu, Liangru Zhu, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 3, pp. 892-900
Open Access | Times Cited: 5
Biomarkers related to immune checkpoint inhibitors therapy
Na Li, Xin Hou, Shaogang Huang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112470-112470
Open Access | Times Cited: 21
Neurological Complications of Conventional and Novel Anticancer Treatments
Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6088-6088
Open Access | Times Cited: 21
Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature
Syed Ali, Preethi Vembar, Shawgi Sukumaran, et al.
Immunotherapy (2023) Vol. 15, Iss. 14, pp. 1125-1132
Closed Access | Times Cited: 12
Preclinical models of immune checkpoint inhibitors-related interstitial pneumonia for anti-PD1 tumor immunotherapy
Tingyue Luo, Wei‐Sheng Chen, Danhui Huang, et al.
Immunobiology (2025) Vol. 230, Iss. 2, pp. 152884-152884
Open Access
Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions
Yan Xu, Ruxuan Chen, Ruili Pan, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2025) Vol. 3, Iss. 1, pp. 29-40
Open Access
Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma
Nasreen Abdul Aziz, David Burke, Sharanniyan Ragavan, et al.
JCO Oncology Practice (2025)
Closed Access
Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline
Dirk De Ruysscher, Els Wauters, Verena Jendrossek, et al.
Radiotherapy and Oncology (2025), pp. 110837-110837
Open Access
Management of refractory checkpoint inhibitor-induced colitis
Anas Zaher, Maria José Albuquerque Santos, Hassan Elsaygh, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Page 1 - Next Page

Scroll to top